S. 1114 · 118th Congress · Health

Expanding Access to Low-Cost Generics Act of 2023

Died in the Senate2.1k words Introduced Mar 30, 2023 · Latest action Jun 22, 2023

How far it has goneStopped at 3 of 6 · Died in the Senate
  1. IntroducedMar 30, 2023 Done
  2. CommitteeReported Jun 22, 2023 Done
  3. Senate floorDied Jan 3, 2025 Stopped here
  4. House floorNot yet Not reached yet
  5. Chambers agreeNot yet Not reached yet
  6. PresidentNot yet Not reached yet

What it does

This bill modifies provisions related to market exclusivity for a generic drug.

Currently, the Food and Drug Administration (FDA) awards 180 days of exclusivity on the market to a first applicant to file a qualifying application for market approval of a generic drug. Generally, this exclusivity period begins upon a first applicant's commercial marketing of the drug.

The bill authorizes the FDA to approve a subsequent generic drug application prior to a first applicant's first date of commercial marketing if (1) the subsequent application is ready for full approval, (2) the applicant certifies that there are no conditions that would prevent commercial marketing of the drug within 75 days of approval and that the applicant intends to do so, (3) a first applicant's application has been pending for at least 33 months, (4) the approval of a first applicant's application is not precluded by patent infringement claims asserted against that first applicant, and (5) no first applicant's application has been effectively approved on the date that all such conditions are met.

If an applicant fails to begin commercially marketing their drug within 75 days of approval via the aforementioned process, the applicant's approval is deemed tentative and the applicant is no longer eligible for subsequent approvals, unless the applicant certifies that the failure was due to unforeseen issues that have since been resolved.

Additionally, the FDA must inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why).

Congressional Research Service · summary of “Reported to Senate” version · Jun 22, 2023

Who lobbies on it

10 organizations · 53 filings · Q1 2023–Q4 2024

One square per quarter since introduction, oldest left. Filled = named it that quarter.

  1. Chamber of Commerce of the U.s.a. 7 of 8 quarters
    “H.R. 1264, Commonsense Reporting Act of 2023 H.R. 2813, Self-Insurance Protection Act H.R. 2868, Association Health Plans Act H.R. 3800, Chronic Disease Flexible Coverage Act H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues…”

    Q4 2024 filing · $74.5M lobbying spend in 2024, all issues

  2. Pharmaceutical Research and Manufacturers of America 7 of 8 quarters
    “340B drug discount program; drug pricing; importation of biopharmaceuticals; direct-to-consumer (DTC) advertising; transparency; international pharmaceutical supply chain; antimicrobial resistance legislation; insulin price cap; DoD TRICARE Pharmacy Benefits Program, H.R.8070/S.4638, National Defense Authorization Act…”

    Q4 2024 filing · $31.0M lobbying spend in 2024, all issues

  3. Teva Pharmaceuticals Usa Inc 7 of 8 quarters
    “Use of Section viii statements in pharmaceutical labeling. FDAs approval of over-the-counter naloxone nasal spray. Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform…”

    Q4 2024 filing · $2.3M lobbying spend in 2024, all issues

7 more organizations, every filingPROUpgrade

Organizations that named S. 1114 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. Source: Senate lobbying disclosures (LD-2) from lda.gov; quotes are word for word from the “specific lobbying issues” field.

Actions

5 actions · newest first
  1. Jun 22, 2023Placed on Senate Legislative Calendar under General Orders. Calendar No. 108.
  2. Jun 22, 2023Committee on Health, Education, Labor, and Pensions. Reported by Senator Sanders with an amendment in the nature of a substitute. Without written report.
  3. May 11, 2023Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
  4. Mar 30, 2023Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Show all 5 actionsShow fewer
  1. Mar 30, 2023Introduced in Senate